Stock analysts at TD Cowen initiated coverage on shares of CeriBell (NASDAQ:CBLL – Get Free Report) in a research report issued to clients and investors on Tuesday, Marketbeat reports. The firm set a “buy” rating and a $31.00 price target on the stock. TD Cowen’s target price indicates a potential upside of 11.59% from the stock’s current price.
Separately, William Blair assumed coverage on shares of CeriBell in a research report on Tuesday. They set an “outperform” rating for the company. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $31.00.
Get Our Latest Stock Analysis on CeriBell
CeriBell Stock Performance
CeriBell Company Profile
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Featured Articles
- Five stocks we like better than CeriBell
- What is the S&P 500 and How It is Distinct from Other Indexes
- What a Trump Win Looks Like for the Market Now and Into 2025
- How to Calculate Inflation Rate
- Russell 2000 Surge Post-Election: How to Play the Small-Cap Pop
- Consumer Staples Stocks, Explained
- Macro Headwinds Send Microchip Technology Stock to the Buy Zone
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.
